
|Articles|October 1, 2002
Commitment to R&D strengthens Allergan product pipeline
Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Laru-zova meets primary endpoint in pivotal VISTA trial for X-linked retinitis pigmentosa
2
EyeCon 2026: ODs and MDs pull up a chair
3
Addressing geographic variation in dry eye disease care requires patient-centric approaches
4
How screen time and eyelid health affect dry eye risk
5











